Vaccination of mice with DNA encoding a large fragment of botulinum neurotoxin serotype A.
The potential utility of using DNA vaccination to protect mice from the microbial neurotoxin, botulinum toxin type A, was evaluated. A synthetically derived gene encoding a carboxyl-terminal 50 kDa fragment of the toxin was placed in two sites in the DNA inoculation vehicle pCMVint-BL (Vical), one predicted to lead to MHC I processing (pJT-1 construct) and the other to direct MHC II processing (pJT-2 construct). Mice were then inoculated at 3 week intervals with these two constructs and with the vehicle alone and evaluated for protection from botulinum toxin by i.p. challenges with various toxin doses. Protection was observed at about week 10-11 from toxin doses of 25-100 LD(50). Only animals inoculated with pJT-2 exhibited protection. In dose-response experiments, 50 micrograms of DNA was the minimal dose required to elicit a protective response against serotype A, while protection against serotypes B or E was not obtained. With standard ELISA testing, a relationship was observed between the level of protection and the level of ELISA reactive antibody. Our results support the concept that DNA vaccination is a viable methodology to use in cases where protection from toxins is the goal.
Clayton
J
J
Virology Division, US Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Middlebrook
J L
JL
D000818:Animals; D000906:Antibodies / Q000097:blood; D019274:Botulinum Toxins, Type A / Q000235:genetics / Q000276:immunology* / Q000633:toxicity; D001906:Botulism / Q000097:blood / Q000517:prevention & control*; D004306:Dose-Response Relationship, Immunologic; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005822:Genetic Vectors / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use; D007928:Lethal Dose 50; D051379:Mice; D008807:Mice, Inbred BALB C; D010446:Peptide Fragments / Q000235:genetics / Q000276:immunology*; D015996:Survival Rate; D019444:Vaccines, DNA / Q000235:genetics / Q000276:immunology / Q000302:isolation & purification / Q000627:therapeutic use*
D000906:Antibodies; D010446:Peptide Fragments; D019444:Vaccines, DNA; D019274:Botulinum Toxins, Type A